Literature DB >> 27046143

Computational modeling in melanoma for novel drug discovery.

Marzio Pennisi1, Giulia Russo2, Valentina Di Salvatore3, Saverio Candido2, Massimo Libra2, Francesco Pappalardo4.   

Abstract

INTRODUCTION: There is a growing body of evidence highlighting the applications of computational modeling in the field of biomedicine. It has recently been applied to the in silico analysis of cancer dynamics. In the era of precision medicine, this analysis may allow the discovery of new molecular targets useful for the design of novel therapies and for overcoming resistance to anticancer drugs. According to its molecular behavior, melanoma represents an interesting tumor model in which computational modeling can be applied. Melanoma is an aggressive tumor of the skin with a poor prognosis for patients with advanced disease as it is resistant to current therapeutic approaches. AREAS COVERED: This review discusses the basics of computational modeling in melanoma drug discovery and development. Discussion includes the in silico discovery of novel molecular drug targets, the optimization of immunotherapies and personalized medicine trials. EXPERT OPINION: Mathematical and computational models are gradually being used to help understand biomedical data produced by high-throughput analysis. The use of advanced computer models allowing the simulation of complex biological processes provides hypotheses and supports experimental design. The research in fighting aggressive cancers, such as melanoma, is making great strides. Computational models represent the key component to complement these efforts. Due to the combinatorial complexity of new drug discovery, a systematic approach based only on experimentation is not possible. Computational and mathematical models are necessary for bringing cancer drug discovery into the era of omics, big data and personalized medicine.

Entities:  

Keywords:  Computational modeling; in silico drug discovery; melanoma; systems biology

Mesh:

Substances:

Year:  2016        PMID: 27046143     DOI: 10.1080/17460441.2016.1174688

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  8 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

2.  Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus.

Authors:  Marzio Pennisi; Giulia Russo; Silvia Ravalli; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2017-12-28       Impact factor: 3.169

3.  Phenotype characterization of human melanoma cells resistant to dabrafenib.

Authors:  Fabiola Gilda Cordaro; Anna Lisa De Presbiteris; Rosa Camerlingo; Nicola Mozzillo; Giuseppe Pirozzi; Ernesta Cavalcanti; Antonella Manca; Giuseppe Palmieri; Antonio Cossu; Gennaro Ciliberto; Paolo A Ascierto; Salvatore Travali; Eduardo J Patriarca; Emilia Caputo
Journal:  Oncol Rep       Date:  2017-09-18       Impact factor: 3.906

Review 4.  Cutaneous melanoma: From pathogenesis to therapy (Review).

Authors:  Giulia C Leonardi; Luca Falzone; Rossella Salemi; Antonino Zanghì; Demetrios A Spandidos; James A Mccubrey; Saverio Candido; Massimo Libra
Journal:  Int J Oncol       Date:  2018-02-27       Impact factor: 5.650

5.  In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical products.

Authors:  Marco Viceconti; Francesco Pappalardo; Blanca Rodriguez; Marc Horner; Jeff Bischoff; Flora Musuamba Tshinanu
Journal:  Methods       Date:  2020-01-25       Impact factor: 3.608

6.  Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.

Authors:  Lindsey Enewold; Elad Sharon; Linda C Harlan
Journal:  Oncol Res Treat       Date:  2017-03-09       Impact factor: 2.844

Review 7.  The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Michelle Atallah; Garth W Tormoen; Joseph J Shatzel; Samuel Tassi Yunga; Todd H Wagner; John T Leppert; Parag Mallick; Owen J T McCarty
Journal:  Front Oncol       Date:  2018-03-21       Impact factor: 6.244

Review 8.  Current Strategies and Applications for Precision Drug Design.

Authors:  Chen Wang; Pan Xu; Luyu Zhang; Jing Huang; Kongkai Zhu; Cheng Luo
Journal:  Front Pharmacol       Date:  2018-07-18       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.